Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 237 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: U.S. Army Medical Research and Development Command Clear all

Conditions: PTSD
Interventions: SRX246, Placebo; Drug
Lead sponsor: Azevan Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Duchenne Muscular Dystrophy (DMD)
Interventions: Prednisone, Exercise Training on standard steroid regimen, Exercise training on twice-weekly steroids; Drug · Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 5 Years to 9 Years · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Post Traumatic Stress Disorder
Interventions: Intervention A Fluoxetine Hydrochloride (HCl), Intervention A Placebo, Intervention B Vilazodone Hydrochloride (HCl), Intervention B Placebo, Intervention C Daridorexant, Intervention C Placebo, Intervention D SLS-002, Intervention D Placebo; Drug
Lead sponsor: Global Coalition for Adaptive Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2029
U.S. locations: 9
States / cities: Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more

Conditions: Malaria,Falciparum
Interventions: Plasmodium falciparum malaria parasite; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Eye-tracking
Interventions: EYE-SYNC eye-tracking device, SCAT-3, Desktop Eye-Tracker; Device · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 25 Years
Enrollment: 155 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Breast Cancer
Interventions: Prospective intervention; Behavioral
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 40 Years and older · Female only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy Volunteers
Interventions: Almorexant, Zolpidem 10mg, Placebo; Drug
Lead sponsor: Northern California Institute of Research and Education; Other
Eligibility: 19 Years to 39 Years
Enrollment: 203 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diabetes Mellitus, Type 2
Interventions: Mobile Health Care Environment (MHCE); Other
Lead sponsor: Clemson University; Other
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Nellis Air Force Base, Nevada • Tacoma, Washington

Conditions: Escherichia Coli Infection
Interventions: Recombinant fimbrial adhesin dscCfaE, Modified E. coli heat labile enterotoxin LTR192G; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Freeze Dried Plasma in Healthy Volunteers
Interventions: Autologous Freeze Dried Plasma (FDP), Fresh Frozen Plasma (FFP); Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Dengue Fever
Interventions: 4 µg TDENV-PIV with Alum adjuvant, 1 µg TDENV-PIV with AS03B1 adjuvant, Phosphate buffered saline, 1 µg TDENV-PIV with Alum adjuvant, 1 µg TDENV-PIV with AS01E1 adjuvant; Biological · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 39 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Malaria
Interventions: FMP012 with AS01B adjuvant system, P falciparum Controlled Human Malaria Infection (CHMI); Biological · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 50 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Healthy
Interventions: Neuro Kinetics, Inc, i-PAS; Device
Lead sponsor: Uniformed Services University of the Health Sciences; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Bethesda, Maryland • Charleston, South Carolina

Conditions: Malaria
Interventions: Mefloquine, Control; Drug · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Anxiety Disorders, Mood Disorders, Insomnia, Nightmares
Interventions: Behavioral Sleep Intervention, Prazosin, Placebo; Behavioral · Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Metastatic Breast Cancer
Interventions: WX-671, placebo; Drug
Lead sponsor: Heidelberg Pharma AG; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 3
States / cities: New York, New York • Cleveland, Ohio • Philadelphia, Pennsylvania

Conditions: Difficulties, Ambulation, Brain Injuries, Traumatic
Interventions: Intensive Mobility Training (IMT); Behavioral
Lead sponsor: INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Traumatic Brain Injury
Interventions: Cyclosporine (CsA), Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: San Francisco, California • Cincinnati, Ohio • Pittsburgh, Pennsylvania + 1 more

Conditions: Pharmacokinetics, Metabolism
Interventions: permethrin insecticide; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 50 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Mather, California

Conditions: Healthy Volunteers
Interventions: Acellular Adipose Tissue (AAT); Biological
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Venezuelan Equine Encephalomyelitis Virus Disease
Interventions: VEE Vaccine; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Fort Deterick, Maryland

Conditions: Hemorrhagic Fever With Renal Syndrome
Interventions: HTNV/PUUV DNA vaccine, Placebo, TriGrid Delivery System (TDS); Biological · Device
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 49 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Plasmodium Vivax Malaria
Interventions: Malaria Challenge; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Low Back Pain, Herniation, Disc, Sciatic Radiculopathy, Intervertebral Disc Stenosis of Neural Canal, Intervertebral Disc Injury
Interventions: NSSD, Sham NSSD; Device
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Stanford, California • Tampa, Florida

Search by objective public record fields.

Proof-of-concept Study to Assess the Efficacy and Safety of SRX246 in Adults With PTSD

Twice Weekly Steroids and Exercise as Therapy for DMD

Department of Defense PTSD Adaptive Platform Trial - Master Protocol

Evaluate the Infectivity Equivalence of Current and New Lots of Plasmodium Falciparum Strain NF54

EYE-TRAC Advance: Technology Verification (ETA-TV) Cohort 1

Increasing Adherence to Follow-up of Breast Abnormalities in Low-Income Korean American Women

Effect of a Hypocretin/Orexin Antagonist on Neurocognitive Performance

Enhancing mHealth Technology to Activate Chronic Care Patients

Safety Study of Recombinant Vaccine to Prevent ETEC Diarrhea

Ascending Doses of Autologous FDP vs FFP

A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults

Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults

Test and Evaluation of Non-Invasive Neuro-Assessment Devices (NINAD): NeuroKinetics, Inc, iPAS

Merozoite Surface Protein 1 Antibody Response in Asymptomatic Human Malaria Infection

Efficacy of Sleep Interventions for Posttraumatic Stress Disorder (PTSD)

Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer

Walking and Balance Post-TBI

TRACK-TBI Precision Medicine Part 3 - Option II

Metabolism of the Insecticide Permethrin

Safety Study of Acellular Adipose Tissue for Soft Tissue Reconstruction

Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine in Healthy Adults

Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever

Clinical Trial for the Development of a Safe Malaria Challenge Model That Can be Reproduced in Humans

Non-surgical Spinal Decompression Therapy and Outcomes